PRA Health Sciences, a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv™ platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, processes, and people across every aspect of a clinical study, Predictivv™ will enable unprecedented adaptive intelligence and decision support for the ever-increasing complexities of the clinical development process.
“Predictivv™ is another step in PRA’s ambitious goal to change the future of clinical development,” said CEO Colin Shannon. “As we enter a new era of clinical development led by ideas like adaptive trial design and riskâbased monitoring, we recognized that existing clinical-trial management solutions did not support the realâtime modifications of protocols and operational plans required by adaptive models and the high risks associated with managing this complexity.”
The Predictivv™ platform will seamlessly bring together a series of clinical study applications representing the foundation of a true end-to-end clinical development process. Predictivv™ combines data input and continuous feedback from across the spectrum of the trial process, empowering decision support intelligence throughout the entire clinical lifecycle.
“One of the primary goals we established when designing the Predictivv platform was to provide the industry with unprecedented transparency into their portfolio of studies,” said Shannon. Through a proprietary analytics engine, Predictivv™ will not only provide transparency into all key processes and their statuses, but it will be capable of proactively identifying process and protocol deviations, enabling course corrections before risks occur.
Among the first applications that will be available in the PredictivvTM platform is Predictivv Connect™. Connect is a highly configurable solution that provides real time insights into every phase of clinical trial management, empowering clients and key stakeholders to connect and use data within their studies in an entirely new way.
With its investment in the Predictivv™ platform, PRA anticipates launching several new applications that focus on key aspects of clinical trial management, including areas such as site selection, patient recruitment and investigator engagement. PredictivvTM applications will be device independent, allowing users to explore data, uncover new insights and take action instantly from any device.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.